The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1

Oncotarget

Volumn 6, Issue 11, 2015, Pages 8851-8874

  Liu, Wensheng ^a,b   Yue, Fei ^a   Zheng, Minhua ^a   Merlot, Angelica ^b   Bae, Dong Hun ^b   Huang, Michael ^b   Lane, Darius ^b   Jansson, Patric ^b   Liu, Goldie ^b   Richardson, Vera ^b   Sahni, Sumit ^b   Kalinowski, Danuta ^b   Kovacevic, Zaklina ^b   Richardson, Des R ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

C Src; Cell migration; Metastasis suppressor; NDRG1

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; ABELSON KINASE; CRK ASSOCIATED SUBSTRATE PROTEIN; CRK LIKE PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MYC PROTEIN; N MYC DOWNSTREAM REGULATED GENE 1; P21 ACTIVATED KINASE 1; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; RAC1 PROTEIN; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; BCAR1 PROTEIN, HUMAN; CELL CYCLE PROTEIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; INDOLE DERIVATIVE; N-MYC DOWNSTREAM-REGULATED GENE 1 PROTEIN; ONCOPROTEIN; P21 ACTIVATED KINASE; PAK1 PROTEIN, HUMAN; PROTEIN KINASE P60; RAC1 PROTEIN, HUMAN; RECOMBINANT PROTEIN; SIGNAL PEPTIDE; SULFONAMIDE; TUMOR PROTEIN;

ARTICLE; CELL ADHESION; CELL MIGRATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; IMMUNOPRECIPITATION; METASTASIS INHIBITION; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL MOTION; COLON TUMOR; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; ONCOGENE SRC; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROSTATE TUMOR; PROTEIN PROCESSING; RNA INTERFERENCE; TUMOR CELL LINE;

ADENOCARCINOMA; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; CRK-ASSOCIATED SUBSTRATE PROTEIN; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, SRC; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEOPLASM PROTEINS; P21-ACTIVATED KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-CRK; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RAC1 GTP-BINDING PROTEIN; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84928733846     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3316     Document Type: Article

References (82)

1. Christofori G. New signals from the invasive front. Nature. 2006; 441:444-450.
2. Christofori G. Changing neighbours, changing behaviour cell adhesion molecule-mediated signalling during tumour progression. EMBO J. 2003; 22:2318-2323.
3. Guarino M. Src signaling in cancer invasion. J Cell Physiol. 2010; 223:14-26.
4. Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. Oncologist. 2009; 14:667-678.
5. Roskoski R Jr. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun. 2005; 331:1-14.
6. Lessard L, Stuible M, Tremblay ML. The two faces of PTP1B in cancer. Biochim Biophys Acta. 2010; 1804:613-619.
7. Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest. 1993; 91:53-60.
8. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008; 68:3323-3333.
9. Nagathihalli NS, Merchant NB. Src-mediated regulation of E-cadherin and EMT in pancreatic cancer. Front Biosci. 2012; 17:2059-2069.
10. Reynolds AB, Kanner SB, Bouton AH, Schaller MD, Weed SA, Flynn DC, Parsons JT. SRChing for the substrates of Src. Oncogene. 2013; 33:4537-4547.
11. Defilippi P, Di Stefano P, Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol. 2006; 16:257-263.
12. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol. 2004; 265:23-32.
13. Sharma A, Mayer BJ. Phosphorylation of p130Cas initiates Rac activation and membrane ruffling. BMC Cell Biol. 2008; 9:50.
14. Plattner R, Kadlec L, DeMali KA, Kazlauskas A. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Gene Dev. 1999; 13:2400-2411.
15. Abassi YA, Vuori K. Tyrosine 221 in Crk regulates adhesion- dependent membrane localization of Crk and Rac and activation of Rac signaling. EMBO J. 2002; 21:4571-4582.
16. Zandy NL, Playford M, Pendergast AM. Abl tyrosine kinases regulate cell cell adhesion through Rho GTPases. Proc Natl Acad Sci U S A. 2007; 104:17686-17691.
17. Filic V, Marinovic M, Faix J, Weber I. A dual role for Rac1 GTPases in the regulation of cell motility. J Cell Sci. 2012; 125:387-398.
18. Servitja JM, Marinissen MJ, Sodhi A, Bustelo XR, Gutkind JS. Rac1 function is required for Src-induced transformation. Evidence of a role for Tiam1 and Vav2 in Rac activation by Src. J Biol Chem. 2003; 278:34339-34346.
19. Hurst DR, Welch DR. Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol. 2011; 286:107-180.
20. Salnikow K, Kluz T, Costa M, Piquemal D, Demidenko ZN, Xie K, Blagosklonny MV. The regulation of hypoxic genes by calcium involves c-Jun/AP-1, which cooperates with hypoxia-inducible factor 1 in response to hypoxia. Mol Cell Biol. 2002; 22:1734-1741.
21. Mao Z, Sun J, Feng B, Ma J, Zang L, Dong F, Zhang D, Zheng M. The metastasis suppressor, N-myc downregulated gene 1 (NDRG1), is a prognostic biomarker for human colorectal cancer. PLoS One. 2013; 8:e68206.
22. Liu R, Li J, Teng Z, Zhang Z. Overexpressed microRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream regulated gene 1. PLoS One. 2013; 16:e68982.
23. Song Y, Lv L, Du J, Yue L, Cao L. Correlation of N-myc downstream-regulated gene 1 subcellular localization and lymph node metastases of colorectal neoplasms. Biochem Biophys Res Commun. 2013; 439:241-246.
24. Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, Saito K, Commes T, Hayashi S, Watabe M, Watabe K. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res. 2003; 63:1731-1736.
25. Bae DH, Jansson PJ, Huang ML, Kovacevic Z, Kalinowski D, Lee CS, Sahni S, Richardson DR. The role of NDRG1 in the pathology and potential treatment of human cancers. J Clin Pathol. 2013; 66:911-917.
26. Dixon KM, Lui GY, Kovacevic Z, Zhang D, Yao M, Chen Z, Dong Q, Assinder SJ, Richardson DR. Dp44mT targets the AKT, TGF-beta and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. Br J Cancer. 2013; 108:409-419.
27. Hosoi F, Izumi H, Kawahara A, Murakami Y, Kinoshita H, Kage M, Nishio K, Kohno K, Kuwano M, Ono M. N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression. Cancer Res. 2009; 69:4983-4991.
28. Liu W, Xing F, Iiizumi-Gairani M, Okuda H, Watabe M, Pai SK, Pandey PR, Hirota S, Kobayashi A, Mo Y-Y, Fukuda K, Li Y, Watabe K. N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med. 2012; 4:93-108.
29. Chen Z, Zhang D, Yue F, Zheng M, Kovacevic Z, Richardson DR. The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1. J Biol Chem. 2012; 287:17016-17028.
30. Jin R, Liu W, Menezes S, Yue F, Zheng M, Kovacevic Z, Richardson DR. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of betacatenin through mechanisms involving FRAT1 and PAK4. J Cell Sci. 2014; 127:3116-3130.
31. Sun J, Zhang D, Zheng Y, Zhao Q, Zheng M, Kovacevic Z, Richardson DR. Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway. Mol Pharmacol. 2012; 83:454-469.
32. Murray JT CD, Morrice N, Auld GC, Shpiro N, Marquez R, Peggie M, Bain J, Bloomberg GB, Grahammer F, Lang F, Wulff P, Kuhl D, Cohen P. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J. 2004; 384:477-488.
33. Kovacevic Z, Sivagurunathan S, Mangs H, Chikhani S, Zhang D, Richardson DR. The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis. 2011; 32:732-740.
34. Okada M. Regulation of the SRC family kinases by Csk. Int J Biol Sci. 2012; 8:1385-1397.
35. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene. 2004; 23:7918-7927.
36. Krishnan H, Miller WT, Goldberg GS. SRC points the way to biomarkers and chemotherapeutic targets. Genes Cancer. 2012; 3:426-435.
37. Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta. 2008; 1784:56-65.
38. Huveneers DE. Adhesion signaling - crosstalk between integrins, Src and Rho. J Cell Sci. 2009; 122:1059-1069.
39. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004; 23:7957-7968.
40. Holbro T. The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003; 284:99-110.
41. Lombardo CR, Consler TG, Kassel DB. In vitro phosphorylation of the epidermal growth factor receptor autophosphorylation domain by c-src identification of phosphorylation sites and c-src SH2 domain binding sites. Biochemistry. 1995; 34:16456-16466.
42. Leu TH, Maa MC. Functional implication of the interaction between EGF receptor and c-Src. Front Biosci. 2003; 8:28-38.
43. Jorissen R. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003; 284:31-53.
44. Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011; 144:703-718.
45. Klemke L, Leng Molander, Brooks C, Vuori A. CAS/Crk coupling serves as a molecular switch for induction of cell migration. J Cell Biol. 1998; 140:961-972.
46. Feng H, Hu B, Liu KW, Li Y, Lu X, Cheng T, Yiin JJ, Lu S, Keezer S, Fenton T, Furnari FB, Hamilton RL, Vuori K, et al. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. J Clin Invest. 2011; 121:4670-4684.
47. Zhu G, Wang Y, Huang B, Liang J, Ding Y, Xu A, Wu W. A Rac1/PAK1 cascade controls beta-catenin activation in colon cancer cells. Oncogene. 2012; 31:1001-1012.
48. Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R. PAK signaling in oncogenesis. Oncogene. 2009; 28:2545-2555.
49. Srinivasan D, Plattner R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res. 2006; 66:5648-5655.
50. Sirvent A, Boureux A, Simon V, Leroy C, Roche S. The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells. Oncogene. 2007; 26:7313-7323.
51. Bradley WD, Koleske AJ. Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts. J Cell Sci. 2009; 122:3441-3454.
52. Stuart JR, Gonzalez FH, Kawai H, Yuan ZM. c-Abl interacts with the WAVE2 signaling complex to induce membrane ruffling and cell spreading. J Biol Chem. 2006; 281:31290-31297.
53. Birge RB, Kalodimos C, Inagaki F, Tanaka S. Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun Signal. 2009; 7:13.
54. Hickok JR, Sahni S, Mikhed Y, Bonini MG, Thomas DD. Nitric oxide suppresses tumor cell migration through N-Myc downstream-regulated gene-1 expression: role of chelatable iron. J Biol Chem. 2011; 286:41413-41424.
55. Le NTV, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood. 2004; 104:2967-2975.
56. Kovacevic Z, Chikhani S, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Mol Pharmacol. 2011; 80:598-609.
57. Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridylderived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood. 2004; 104:1450-1458.
58. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A. 2006; 103:14901-14906.
59. Lovejoy DB, Sharp DM, Seebacher N, Obeidy P, Prichard T, Stefani C, Basha MT, Sharpe PC, Jansson PJ, Kalinowski DS, Bernhardt PV, Richardson DR. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J Med Chem. 2012; 55:7230-7244.
60. Sahni S, Bae DH, Lane DJ, Kovacevic Z, Kalinowski DS, Jansson PJ, Richardson DR. The metastasis suppressor, N-myc downstream-regulated gene 1 , inhibits stressinduced autophagy in cancer cells. J Biol Chem. 2014; 289:9692-9709.
61. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005; 57:547-583.
62. Gutierrez E, Richardson DR, Jansson PJ. The anti-cancer agent, Dp44mT, overcomes pro-survival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity. J Biol Chem. 2014; 289:33568-33589.
63. Merlot AM, Pantarat N, Menezes SV, Sahni S, Richardson DR, Kalinowski DS. Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanism. Mol Pharmacol. 2013; 84:911-924.
64. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, Sznol M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol. 2004; 22:1553-1563.
65. Chao J, Synold TW, Morgan RJ Jr., Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, et al. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2012; 69:835-843.
66. Richardson D, Ponka P, Baker E. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res. 1994; 54:685-689.
67. Kovacevic Z, Fu D, Richardson DR. The iron-regulated metastasis suppressor, Ndrg-1: Identification of novel molecular targets. Biochimica Biophysica Acta. 2008; 1783:1981-1992.
68. Sun J, Zhang D, Bae DH, Sahni S, Jansson P, Zheng Y, Zhao Q, Yue F, Zheng M, Kovacevic Z, Richardson DR. Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis. 2013; 34:1943-1954.
69. Fang BA, Kovacevic Z, Park KC, Kalinowski DS, Jansson PJ, Lane DJ, Sahni S, Richardson DR. Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy. Biochim Biophys Acta. 2014; 1845:1-19.
70. Park JJ, Jin YB, Lee YJ, Lee JS, Lee YS, Ko YG, Lee M. KAI1 suppresses HIF-1alpha and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer. BMC Cancer. 2012; 12:81.
71. Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene. 2006; 25:2367-2378.
72. Zhang XA, He B, Zhou B, Liu L. Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/ CD82-mediated inhibition of cell migration. J Biol Chem. 2003; 278:27319-27328.
73. Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 2006; 16:522-529.
74. Szczepanowska J. Involvement of Rac-Cdc42-PAK pathway in cytoskeletal rearrangements. Acta Biochim Pol. 2009; 56:225-234.
75. Coniglio SJ, Zavarella S, Symons MH. Pak1 and Pak2 mediate tumor cell invasion through distinct signaling mechanisms. Mol Cell Biol. 2008; 28:4162-4172.
76. Park TJ, Curran T. Essential roles of Crk and CrkL in fibroblast structure and motility. Oncogene. 2014; 33:5121-5132.
77. Sriram G, Jankowski W, Kasikara C, Reichman C, Saleh T, Nguyen KQ, Li J, Hornbeck P, Machida K, Liu T, Li H, Kalodimos CG, Birge RB. Iterative tyrosine phosphorylation controls non-canonical domain utilization in Crk. Oncogene. 2014; doi:10.1038/onc.2014.361.
78. Lane DJ, Saletta F, Suryo Rahmanto Y, Kovacevic Z, Richardson DR. N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. PLoS One. 2013; 8:e57273.
79. Ghalayini MK, Dong Q, Richardson DR, Assinder SJ. Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells. Biosci Rep. 2013; 33:451-461.
80. Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, Bernhardt PV. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem. 2006; 49:6510-6521.
81. Lovejoy DB, Sharp DM, Seebacher N, Obeidy P, Prichard T, Stefani C, Basha MT, Sharpe PC, Jansson PJ, Kalinowski DS, Bernhardt PV, Richardson DR. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J Med Chem. 2012; 55:7230-7244.
82. Gao J, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood. 2001; 98:842-850.